Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

References

• Parma M, Viganò C, Fumagalli M, et al. Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission. Mediterr J Hematol Infect Dis. 2015;7:e2015041.
   PubMed Web of Science ®Google Scholar
• Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189–3197.
   PubMed Web of Science ®Google Scholar
• Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005;105:3434–3441.
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Slovak ML, Kopecky KJ, et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111:2563–2572.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica. 2002;87:154–166.
   PubMed Web of Science ®Google Scholar
• Marchesi F, Girardi K, Avvisati G. Pathogenetic, clinical, and prognostic features of adult t(4;11)(q21;q23)/MLL-AF4 positive B-cell acute lymphoblastic leukemia. Adv Hematol. 2011;2011:621627. DOI: 10.1155/2011/621627.
   PubMedGoogle Scholar
• Sanjuan-Pla A, Bueno C, Priesto C, et al. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood. 2015;126:2676–2685.
   PubMed Web of Science ®Google Scholar
• Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology. 2011;2011:354–360.
   Google Scholar
• Stein EM, Tallman MS. Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L. Curr Opin Hematol. 2015;22:92–96.
   PubMed Web of Science ®Google Scholar
• Klaus CR, Iwanowicz D, Johnston D, et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther. 2014;350:646–656.
   PubMed Web of Science ®Google Scholar
• Chen CW, Armstrong SA. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol. 2015;43:673–684.
   PubMed Web of Science ®Google Scholar
• Vidriales MB, Pérez JJ, López-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood. 2003;101:4695–4700.
   PubMed Web of Science ®Google Scholar
• Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictor in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739–3749.
   PubMed Web of Science ®Google Scholar
• Shaffer LG, Slovak ML and Campbell LJ, eds. ISCN 2013: an international system for human cytogenetic nomenclatures. Karger: Spokane; 2009.
   Google Scholar
• Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica. 2005;90:1346–1356.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk (HR) Philadelphia chromosome-negative (Ph-) adult acute lymphoblastic leukemia in adolescents and adults according to early cytological response and minimal residual disease after consolidation assessed by flow cytometry: final results of PETHEMA ALL-HR-03 Trial. J Clin Oncol. 2014;32:1595–1604.
   PubMed Web of Science ®Google Scholar
• Ribera JM, García O, Oriol A, et al. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016;41:12–20.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Morgades M, Ciudad J, Barba P, Martino R, Montesinos P, et al. Post-remission treatment with chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) of high-risk (HR) Philadelphia chromosome-negative (Ph-neg) adult acute lymphoblastic leukemia (ALL) according to minimal residual disease (MRD). Preliminary results of the Pethema ALL-HR-11 Trial. Blood. 2015;126:Abstract 1333.
   Google Scholar
• Gokbuget N. How I treat older patients with ALL. Blood. 2013;122:1366–1375.
   PubMed Web of Science ®Google Scholar
• Motlló C, Ribera JM, Morgades M, et al. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Cancer. 2014;120:3958–3964.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Goldstone AH. How I treat acute lymphocytic leukemia in adults. Blood. 2007;110:2268–2279.
   PubMed Web of Science ®Google Scholar
• Yu M, Honoki K, Andersen J, et al. MLL tandem duplication and multiple splicing in adult acute myeloid leukemia with normal karyotype. Leukemia. 1996;10:775–780.
   Web of Science ®Google Scholar
• Sorensen PH, Chen CS, Smith FO, et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest. 1994;93:429–437.
   PubMed Web of Science ®Google Scholar
• Marks DI, Moorman AV, Chilton L, et al. The clinical characteristics, therapy and oucome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica. 2013;98:945–952.
   PubMed Web of Science ®Google Scholar
• Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013;27:2165–2176.
   PubMed Web of Science ®Google Scholar
• Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370:240–250.
   PubMed Web of Science ®Google Scholar
• Burmeister T, Meyer C, Schwartz S, et al. The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood. 2009;113:4011–4015.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Dodge RK, Mrózek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999;93:3983–3993.
   PubMed Web of Science ®Google Scholar
• Pigneux A, Labopin M, Maertens J, et al. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). Leukemia. 2015;29:2375–2381.
   PubMed Web of Science ®Google Scholar